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Serum cortisol levels and 
neuropsychological impairments in 
patients diagnosed with Fibromyalgia
Objective. To describe the relationship between neuro-
psychological variables and serum cortisol levels as a mea-
sure of physiological stress in patients with fibromyalgia.
Methodology. A sample of 60 women was intentionally 
selected: 30 with Fibromyalgia diagnosis and 30 with normal 
controls. Cortisol levels were determined using two blood 
samples (AM and PM) and a neuropsychological and emo-
tional battery was applied with a standardized protocol in 
Colombian population to evaluate different cognitive do-
mains. Comparative and correlational non-parametric ana-
lyzes were performed, a multiple regression analysis to de-
termine influences between variables.
Results. Significant differences between the study 
groups in the neuropsychological variables (attention, mem-
ory, language, visual-constructive praxis and executive 
functions (EF), (p<0.05) were found, obtaining better scores 
in the control group. Significant correlations between the 
cortisol profile, with false acknowledgments of Rey audito-
ry-verbal learning test, and with perseverative errors of the 
Wisconsin test were found. Multiple regression analysis pre-
dicts the influence of memory and EF variables on the corti-
sol profile in an 88.7%.
Conclusions. The findings show that, in patients with 
FM, there are neuropsychological alterations, mainly in ex-
ecutive functioning (cognitive flexibility) and episodic mem-
ory (evocation and storage). Likewise, executive dysfunction 
is related to physiological stress reciprocally and in turn are 
conditioned by emotional alterations such as symptoms of 
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depression, which supports the neurophysiological model 
that compromises the hypothalamic-pituitary-adrenal axis 
and the prefrontal cortex, rich in corticosteroid receptors.
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Niveles de cortisol sérico y alteraciones 
neuropsicológicas en pacientes con diagnóstico 
de Fibromialgia
Objetivo. Describir la relación entre variables neuropsi-
cológicas y niveles de cortisol sérico; como una medida de 
estrés fisiológico; en pacientes con fibromialgia. 
Metodología. Se seleccionó intencionalmente una 
muestra de 60 mujeres: 30 con diagnóstico de Fibromialgia 
y 30 controles normales. Se determinaron los niveles de cor-
tisol mediante dos muestras de sangre (AM y PM) y se realizó 
una batería neuropsicológica y emocional, con un protocolo 
estandarizado en población colombiana para evaluar dife-
rentes dominios cognitivos. Se hicieron análisis comparativo 
y correlacional no paramétrico, un análisis de regresión múl-
tiple para determinar influencias entre las variables.
Resultados. Se encontraron diferencias significativas 
entre los grupos de estudio en las variables neuropsicoló-
gicas (atención, memoria, lenguaje, praxis viso-constructiva 
y funciones ejecutivas (FE), (p<0,05), obteniendo mejores 
puntajes el grupo control. Se hallaron correlaciones signifi-
cativas entre el perfil de cortisol, con falsos reconocimientos 
del test de aprendizaje auditivo verbal de Rey y con errores 
perseverativos del test de Wisconsin. El análisis de regresión 
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INtROduCtION
Fibromyalgia (FM) is a syndrome of chronic affection 
characterized mainly by generalized musculoskeletal pain of 
non-inflammatory cause, accompanied by cognitive com-
plaints, sleep disorders, anxiety and depression. According to 
the criteria established in 2010 by the American College of 
Rheumatology (ACR), these symptoms, to be valid, must be 
reported by the patient persistently in the last 3 months1,2.
FM has a prevalence of 2.1% to 2.9% in the general 
population, being more frequent in women (2.4%) than in 
men (1.8%), showing increases with age: <40 years (0.8%), 
40-59.9 years (2.5%) and <60 (3.0%); and the presence of 
somatic symptoms, anxiety and depression in the manifesta-
tion of the disease3-5. In Latin America, there was an increase 
in cases from 2009 to 2011, probably due to a greater rec-
ognition of the syndrome by the medical community6.
One of the aspects that makes its approach more diffi-
cult are the associated affective-behavioral symptoms. It 
has been found that the coexistence of generalized pain 
with psychiatric conditions leads to a detriment in the qual-
ity of life of people with FM7. In a sample of 5,501 patients 
attending a medical unit in Madrid, it was found that 58% 
had psychiatric illness (non-severe depressive disorder, dys-
thymia, anxiety disorders, phobias, personality disorders and 
adaptive disorders)8. It is also considered that FM can be part 
of a set of syndromes that go through sensitization and cen-
tral hypersensitivity processes, which explains the presence 
of pain and its associated symptoms9.
The repeated presence of pain has also been associated 
with a significant deterioration of cognitive functions, 
which may be affected by the concurrence of affective 
symptoms such as associated anxiety and depression10. Vari-
ous studies have made evident that patients with FM show 
greater deficits in attention, work memory, episodic memory 
and executive functions (inhibitory control, information 
processing speed and decision making), which has also been 
referred to in the literature as “Fibrofog”, understood as a 
variety of cognitive complaints that include precisely diffi-
culties in memory, concentration and mental confusion11-13. 
Other investigators have found difficulties in the response 
of inhibition and attentional control as measured by evoked 
potentials during the execution of an emotional stroop 
task14.
The neurobiological bases of this pathology have not 
yet been defined with certainty, some studies reveal that the 
existence of a sympathetic hyperactivity of the neurons re-
sponsible for the release of corticotropin in the hypothalam-
ic-pituitary-adrenal (HPA) axis, could explain the symptoms 
of the disease and specifically the deficit at cognitive level15. 
It has been shown that cortisol as a steroid hormone re-
leased by the adrenal cortex has effects on memory, brain 
aging and the endocrine response to stress16, as well as in the 
fluctuations of perceived pain17. The exacerbated response 
of pain also causes changes in neuroplasticity, which perpet-
uate its symptoms over time18. 
At present, the diseases associated with the presence of 
chronic pain, are becoming increasingly epidemiological rel-
evance because of the high impact they represent in the 
productivity of the individual and in most aspects of daily 
life and high costs for the systems of health. Due to the 
complexity of the symptomatology and the chronicity in the 
evolution of the natural history of FM, it is important to 
identify the neuropsychological and physiological mecha-
nisms underlying this syndrome, in order to propose new 
treatment options. 
The objective of this research was to study the presence 
of neuropsychological alterations and to determine the in-
fluence that they have on cortisol as a physiological mea-
sure of stress in patients with FM.
MateRIal aNd MethOds
design
The present cross - sectional study was carried out 
through a correlational - causal design, with case - control 
analysis. 
Patients
The sample of subjects with FM was taken from the 
population of patients attending the Colombian Institute of 
Neuropedagogy (Barranquilla, Colombia). The calculation of 
the sample size showed 30 subjects in each study group, 
having as parameters a confidence level of 95% and a test 
múltiple predice la influencia de las variables de memoria y 
FE en el perfil de cortisol en un 88,7%.
Conclusiones. Los hallazgos demuestran que, en pa-
cientes con FM, existen alteraciones neuropsicológicas, prin-
cipalmente en funcionamiento ejecutivo (flexibilidad cog-
nitiva) y memoria episódica (evocación y almacenamiento). 
Igualmente, la disfunción ejecutiva está relacionada con el 
estrés fisiológico de manera recíproca y a su vez son con-
dicionadas por alteraciones emocionales como síntomas de 
depresión, lo cual soporta el modelo neurofisiológico que 
compromete el eje hipotálamo-hipófisis-adrenal y la corteza 
pre-frontal, rica en receptores de córticoesteroides. 
Palabras Clave: Dolor, Fibromialgia, Cortisol, Alteraciones Neuropsicológicas
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power of 80%, average level of cortisol in the morning of 
8.0+0.2 (micrograms/dl) in the control group19 and a mini-
mum standardized mean difference with respect to fibromy-
algia patients 0.73 (micrograms/dl). The sample size was cal-
culated using the program developed by the Information 
Service of the Public Health of General Directorate of the of 
Public Health (Xunta de Galicia), (Directorate General of 
Public Health of the Department of Health, Galicia), in col-
laboration with the Pan American Health Organization (PAHO- 
WHO) Health Analysis and Systems Information. 
The inclusion of the subjects was carried out in an inci-
dental, intentional, non-probabilistic manner provided that 
they met the following inclusion and exclusion criteria: pa-
tients with fibromyalgia diagnosis according to the diagnos-
tic criteria of the American College of Rheumatology2, age 
between 30 and 70 years of age, schooling of 5 years or 
more, and not having a diagnosis of connective tissue diseases 
or a history of cerebrovascular disease (CVD), traumatic 
brain injury, major psychiatric disorders, use of psychoactive 
substances or drugs with action in central nervous system, 
cognitive disability or learning disorders at premorbid level, 
inquired through a semi-structured interview in the pa-
tient’s medical history. For the control group, 30 subjects 
with no pathology or major neurological or psychiatric his-
tory were selected selected according to age, gender and 
schooling criteria according to the group of cases. All sub-
jects signed informed consent to participate in the study. 
Thus, 60 subjects were selected, in their entirety of the 
female gender, which were divided into the two study 
groups: Case Group with FM (30 subjects) and Control Group 
(30 subjects). 
INstRuMeNts 
For the evaluation of neuropsychological variables, a 
protocol of validated evaluation was selected in the Colom-
bian population20 which includes the following instruments: 
1. Minimental state examination – (MMse): A screening 
test used to measure general cognitive functioning in 
the areas of orientation, memory, attention, language 
and visual-constructive praxis. Sensitive to evaluate 
symptoms of dementia or cognitive impairment.
2. Boston Naming test: It was used as a measure of the 
nominative function of the language. This test is part of 
the Boston Aphasia Exam, using in this study the 60 re-
agent version.
3. Controlled Oral Word association test (COWat): A 
word search procedure, used as a measure of language 
fluency and information processing speed.
4. Rey-Osterrieth Complex Figure test (ROCF): As a mea-
sure of visuo-constructive praxis and the ability to or-
ganize the perception of complex visual stimuli. The 
evocation section was used as a measure of visual mem-
ory.
5. Rey auditory-Verbal learning test (RaVlt): Rep-
resents an acoustic-mnemic task that allows the evalu-
ation of verbal episodic memory, ability to learn through 
rehearsal and deferred recall.
6. trail Making test (tMt): A task that involves the ability 
to locate elements in the space used as a selective at-
tention measure (Part A) and to follow sequences as a 
measure of executive functions (Part B).
7. symbol digit test (sdMt): Measures the ability to fo-
cus and execute efficiently (selective attention) the 
working memory, as well as oculomotor agility in the 
written version.
8. stroop color-word test: Taken as a measure of selective 
attention, divided attention and inhibitory control (sec-
tion word-color).
9. token test: Used as a measure of perception and com-
prehension of language by means of verbal instructions 
of increasing complexity.
10. auditory Continuous Performance test (aCPt): Con-
tinuous monitoring task that allows assessing the ability 
to focus and maintain attention (sustained attention).
11. Benton Visual Retention test (BVRt): In addition to 
being sensitive to altered visual memory, it is used as a 
measure of exploration of the ability to sustain atten-
tion as well as resistance to perseveration.
12. Wisconsin Card sorting test (WCst): Used as an exec-
utive performance measure that assesses the ability to 
form abstract concepts and cognitive flexibility.
13. Mental Control - Wechsler Memory scale subtest: 
Used to measure attention control and speed of infor-
mation processing.
14. hamilton anxiety scale and the Beck depression In-
ventory: Used to measure the degree of intensity of 
anxiety and depression symptoms.
Also, blood levels of cortisol (serum free from hemolysis) 
were evaluated as a measure of physiological stress. Samples 
were taken at two times: Serum cortisol AM levels (8:00-
9:00h), with reference values: 4.46-22.7 ug/dl. Serum levels 
of PM cortisol (4:00-5:00h), with reference values: 1.7-14.1 
ug/dl. In addition to the values  obtained in the study group 
and control group, the difference between AM and PM cor-
Serum cortisol levels and neuropsychological impairments in patients diagnosed with 
Fibromyalgia
Ernesto Barceló-Martinez, et al.
4 Actas Esp Psiquiatr 2018;46(1):1-11
tisol was considered for each of the subjects (Profile AM 
-PM).
statistical analysis
The data were analyzed using the SPSS Version 20 for 
social science statistical package. To determine significant 
differences between the study variables, a comparative 
analysis was performed using the non-parametric U test of 
Mann Witney. Subsequently, in the correlation analysis, the 
Sperman statistic was used to establish the relationship be-
tween the study variables, and finally, a multiple regression 
model was applied to evaluate the effect or influence of 
neuropsychological variables on cortisol and a multivariate 
analysis of variance to analyze the influence of affective 
symptoms (anxiety and depression) on the neuropsycholog-
ical profile.
ethical considerations
All investigative processes were guided by ethical stan-
dards established for human research: the Helsinki Declara-
tion of the 2008 World Medical Association, Resolution No. 
008430 of October 4, 1993, of the Ministry of Health of Co-
lombia, on the scientific, technical and administrative stan-
dards for health research, classifying this research as mini-
mum risk and the statutes of the Colombian College of 
Psychologists, COLPSIC: Law 1090 of September 6, 2006. In 
this way, during the development of research, the nature of 
the process and the rights that would be guaranteed were 
socialized with the participants.
Results
In the present investigation, two previously defined 
groups were evaluated: group of cases with diagnosis of FM 
(30 subjects) and control group without some type of pa-
thology (30 subjects). For the FM group, the mean age was 
52 (SD=8.9), with 5 to 12 years of schooling (M=10.2 SD=2.7) 
belonging to an average socio-economic level, which on a 
scale of 1 to 6 corresponds to a socio-economic level 3 and 
4 (M=3.9 SD=1.0). With respect to the time of evolution of 
the disease, 9 women had <1 year of diagnosis, 10 between 
2 and 5 years, 8 between 6 and 10 years, and 3 more than 10 
years. Pain intensity was assessed using the Visual Analog 
Scale of the McGill Pain Inventory21, finding that on a scale 
of 1 to 10, patients reported a level of pain ranging from 6 
to 10 points (ME=7.9 SD=1.86). The patients included in the 
study were not on pharmacological treatment with drugs of 
action on the central nervous system.
For the control group, the mean age was 48.7 years 
(SD=11.1), the average years of schooling was 11.7 (SD=0.6) 
and belong to an average socio-economic level (M=4.0, 
SD=1.4). The control group did not report pain according to 
McGill Visual Analog Scale (ME=0.2, SD=0.81). No differ- 
ences were found in relation to the variables of age, so-
cio-economic stratum and educational level. All subjects 
stated in writing to be willing to participate in the study.
In the descriptive - comparative analysis, significant 
differences (p<0.01) were found with respect to the neuro-
psychological variables between the study groups (Table 1). 
The group with FM, obtained a worse performance in the 
attention tests (TMT-A, Stroop word-color, written and oral 
digit symbol, auditory continuous performance test, Benton 
visual retention test), language (Boston test, Controlled Oral 
Word Association Test, Token test), memory (Rey auditory 
verbal learning test, section A1, A5, A7 trials and recogni-
tion), viso-constructive praxis (Rey-Osterrieth Complex Fig-
ure Test - Copy) and Executive Functions (Stroop Word-col-
or, wisconsin test, mental control). There were no significant 
differences in performance in the Minimental state exam-
ination, false recognition of Rey auditory-verbal learning 
test and TMT B. Regarding the values  obtained from the 
plasma cortisol test AM, PM and the difference between the 
two values  (Profile AM-PM), there were no significant dif-
ferences between the study groups (Table 1).
The Spearman correlational analysis of variables for 
non-parametric samples indicates statistically significant 
correlations in the FM group (Table 2): a moderate negative 
correlation was found between the cortisol profile (AM-PM 
Difference) and False Recognition of the Rey Verbal-Audito-
ry Learning Test and perseverative errors of the Wisconsin 
test. No correlation was found between the neuropsycho-
logical variables and the independent measurements of AM 
and PM cortisol. With regard to the control group, signifi-
cant correlations (p<0.05) were found between Cortisol AM 
with Wisconsin Categories (negative correlation), and Corti-
sol FM with Phonological Verbal Fluency, and with Wiscon-
sin Persevering Errors (Positive Correlations) (Table 3).
Subsequent, to estimate which is the variable that best 
predicts the behavior of the cortisol profile, a multiple re-
gression analysis was performed. The dependent variable is 
the cortisol profile, and the neuropsychological variables, 
anxiety (Hamilton Scale) and depression (Beck Inventory), as 
independent variables. This model explains, in 88.7% (R2) 
the variability of the cortisol profile (corrected R2=77.4%), 
influencing jointly and linearly on this (p-value=0.000).
In the model estimates, the variables with significant val-
ues  (p<0.05) were observed: Minimental State Examination, 
Auditory Continuous Performance Test, Controlled oral word 
association test (phonological and semantic verbal fluency), 
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table 1 description and comparison analysis between study groups
Control Group Group with fibromyalgia
P-Value*
Mean sd Median Mean sd Median
Physiological stress CORTISOL AM 9.23 5.91 8.50 10.31 4.70 10.00 0.134
CORTISOL PM 4.10 1.42 4.00 5.87 3.76 5.00 0.092
PROFILE AM-PM 5.06 5.10 4.00 4.53 3.81 4.00 0.790
Mental status and 
attention 
MMSE 29.73 0.69 30.00 29.29 1.42 30.00 0.206
TMT - A 41.03 14.62 40.00 57.48 26.46 49.00 0.007
STR WORD 107.20 16.93 100.00 85.32 25.16 94.00 0.001
STR COL 71.20 12.55 70.00 60.19 16.04 60.00 0.009
SDMT.WRITTEN 46.53 9.36 48.00 36.71 11.24 35.00 0.000
SDMT ORAL 52.97 11.46 54.50 41.71 11.71 40.00 0.000
ACPT 15.90 0.31 16.00 14.68 2.30 16.00 0.001
BVRT 6.87 1.48 7.00 6.52 4.65 6.00 0.018
Language BOSTON 49.70 4.87 50.00 43.61 7.87 44.00 0.001
COWAT.SEM 35.13 5.34 37.00 29.61 6.34 29.00 0.001
COWAT.PHON 42.20 12.24 42.00 30.61 10.75 31.00 0.001
TOKEN 34.27 1.55 35.00 29.71 6.60 32.00 0.000
Memory RAVLT.A1 5.40 1.30 5.00 4.35 0.84 4.00 0.001
RAVLT.A5 12.77 1.36 13.00 10.39 2.26 10.00 0.000
RAVLT A7 10.90 2.38 11.00 8.06 2.95 8.00 0.000
RAVLT REC 14.53 0.68 15.00 12.19 3.35 13.00 0.000
RAVLT FREC 14.43 0.68 15.00 14.10 1.40 15.00 0.495




35.23 1.33 36.00 32.42 5.08 35.00 0.016
Executive function STR WORD-COL 40.87 9.25 40.00 29.94 14.07 30.00 0.000
WCST CAT 5.30 1.18 6.00 3.45 1.95 4.00 0.000
WCST PERSEV.ERR 16.47 11.10 13.00 34.26 23.47 29.00 0.000
TMT- B 98.97 40.37 83.00 130.61 64.71 119.00 0.052
6.70 1.60 7.00 5.03 2.46 6.00 0.006
* Test U of Mann-Whitney with  significance 0.05
MMSE: Minimental State Examination; TMT-A: Trail Making Test A; TMT-B: Trail Making Test B; SDMT.WRITTEN: Written Digit Symbol; SDMT 
ORAL: Oral Digit Symbol; ACPT: Auditory continuous performance test; BVRT: Benton visual retention test; BOSTON: Test of  denomination 
of Boston COWAT.SEM: Controlled Oral Word Association Test - Semantic Fluidity; COWAT.PHON: Controlled Oral Word Association Test - 
Phonologic Fluidity; TOKEN: Token test; RAVLT: Rey auditory-verbal test (A1 Trial, A5 Trial,  A7 Trial); REC Recognition; FREC False Recognition; 
ROCF EV:  Rey-Osterrieth complex figure test - Evocation; FIG.REY.COP: Rey-Osterrieth complex figure test - Copy; STR.WORD: Stroop Word; 
STR.COL: Stroop Color; STR.WORD.COL: Stroop Word Color; WCST CAT: Test of Wisconsin Categories; WCSN PERSEV.ERR: Wisconsin card 
sorting - Perseverative errors; CONTROL MEN: Subscale of Wechsler of Mental Control.
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Rey Verbal-Auditory learning test (A1, A5 trials, recognition 
and false recognition); Rey-Osterrieth complex figure test 
(evocation), Mental Control, Wisconsin Card sorting Test (cat-
egories and perseverative errors) and TMT B and Beck Depres-
sion Inventory. In addition, the variables that most influence 
the cortisol profile are: Rey Verbal- auditory Rey test (Recog-
nition) and the Wisconsin Card Sorting Test (Perseverative 
errors and categories), variables related to memory storage 
processes and Executive Functions (cognitive flexibility and 
abstraction capacity), respectively (Table 4).
table 2 sperman Correlation between cortisol levels and neuropsychological variables in cases group
Neuropsychological tests Cortisol aM Cortisol PM difference aM-PM
MMSE Correlation coefficient 0.061 0.294 -0.030
TMT A Correlation coefficient 0.090 -0.129 0.228
TMT B Correlation coefficient 0.129 -0.141 0.333
SDMT.WRITTEN Correlation coefficient -0.251 -0.091 -0.279
SDMT ORAL Correlation coefficient -0.144 0.016 -0.285
ACPT Correlation coefficient -0.094 0.262 -0.316
TRVB Correlation coefficient -0.270 0.004 -0.314
BOSTON Correlation coefficient -0.064 0.087 -0.068
COWAT.SEM Correlation coefficient -0.126 0.217 -0.311
COWAT.PHON Correlation coefficient -0.138 0.091 -0.239
TOKEN Correlation coefficient -0.203 0.018 -0.149
RAVLT.A1 Correlation coefficient 0.060 -0.051 0.208
RAVLT.A5 Correlation coefficient 0.252 0.321 0.060
RAVLT A7 Correlation coefficient 0.202 0.302 -0.054
RAVLT REC Correlation coefficient -0.177 0.013 -0.257
RAVLT FREC Correlation coefficient -0.204 0.069 -0.428*
ROCF EV Correlation coefficient -0.354 -0.126 -0.351
ROCF COP Correlation coefficient 0.202 0.239 0.057
STR WORD Correlation coefficient -0.134 0.175 -0.295
STR COL Correlation coefficient -0.004 0.226 -0.200
STR WORD-COL Correlation coefficient -0.001 0.242 -0.240
WCST CAT Correlation coefficient 0.279 0.120 0.283
WCST PERSEV.ERR Correlation coefficient -0.162 0.095 -0.369*
MENTAL CON Correlation coefficient -0.049 0.316 -0.229
*Significant Correlation at 95%** Significant Correlation at 99%.
MMSE: Minimental State Examination; TMT-A: Trail Making Test A; TMT-B: Trail Making Test B; SDMT.WRITTEN: Written Digit Symbol; SDMT ORAL: 
Oral Digit Symbol; ACPT: Auditory continuous performance test; BVRT: Benton visual retention test; BOSTON: Test of  denomination  of Boston 
COWAT.SEM: Controlled Oral Word Association Test - Semantic Fluidity; COWAT.PHON: Controlled Oral Word Association Test - Phonologic Fluidity; 
TOKEN: Token test; RAVLT: Rey auditory-verbal test (A1 Trial, A5 Trial,  A7 Trial); REC Recognition; FREC False Recognition; ROCF EV:  Rey-Osterrieth 
complex figure test - Evocation; FIG.REY.COP: Rey-Osterrieth complex figure test - Copy; STR.WORD: Stroop Word; STR.COL: Stroop Color; STR.
WORD.COL: Stroop Word Color; WCST CAT: Test of Wisconsin Categories; WCSN PERSEV.ERR: Wisconsin card sorting - Perseverative errors; CONTROL 
MEN: Subscale of Wechsler of Mental Control.
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table 3 sperman Correlation between cortisol levels and neuropsychological variables in control group
Neuropsychological tests Cortisol aM Cortisol PM diference aM-PM
MMSE Correlation Coefficient 0.064 -0.072 0.067
TMT A Correlation Coefficient 0.094 -0.072 0.117
TMT B Correlation Coefficient 0.022 -0.112 -0.002
SDMT.WRITTEN Correlation Coefficient -0.190 0.009 -0.134
SDMT ORAL Correlation Coefficient -0.205 0.085 -0.172
ACPT Correlation Coefficient -0.045 -0.188 0.162
TRVB Correlation Coefficient -0.082 0.012 -0.061
BOSTON Correlation Coefficient -0.257 -0.271 -0.274
COWAT.SEM Correlation Coefficient -0.218 -0.133 -0.070
COWAT.PHON Correlation Coefficient 0.025 -0.390* 0.160
TOKEN Correlation Coefficient -0.319 -0.147 -0.265
RAVLT.A1 Correlation Coefficient 0.344 0.063 0.290
RAVLT.A5 Correlation Coefficient -0.232 -0.286 -0.184
RAVLT A7 Correlation Coefficient -0.162 -0.253 -0.133
RAVLT REC Correlation Coefficient -0.014 0.153 -0.068
RAVLT FREC Correlation Coefficient -0.120 -0.253 -0.092
ROCF EV Correlation Coefficient -0.216 0.012 -0.270
ROCF COP Correlation Coefficient 0.021 0.061 -0.016
STR WORD Correlation Coefficient 0.005 0.003 0.031
STR COL Correlation Coefficient -0.207 -0.186 -0.061
STR WORD-COL Correlation Coefficient -0.264 0.009 -0.226
WCST CAT Correlation Coefficient -0.430* -0.244 -0.321
WCST PERSEV.ERR Correlation Coefficient 0.326 0.414* 0.224
MENTAL CON Correlation Coefficient 0.049 -0.105 0.102
*Significant Correlation at 95%** Significant Correlation at 99%.                                                                                  
MMSE: Minimental State Examination; TMT-A: Trail Making Test A; TMT-B: Trail Making Test B; SDMT.WRITTEN: Written Digit Symbol; SDMT ORAL: 
Oral Digit Symbol; ACPT: Auditory continuous performance test; BVRT: Benton visual retention test; BOSTON: Test of  denomination  of Boston 
COWAT.SEM: Controlled Oral Word Association Test - Semantic Fluidity; COWAT.PHON: Controlled Oral Word Association Test - Phonologic Fluidity; 
TOKEN: Token test; RAVLT: Rey auditory-verbal test (A1 Trial, A5 Trial,  A7 Trial); REC Recognition; FREC False Recognition; ROCF EV:  Rey-Osterrieth 
complex figure test - Evocation; FIG.REY.COP: Rey-Osterrieth complex figure test - Copy; STR.WORD: Stroop Word; STR.COL: Stroop Color; STR.
WORD.COL: Stroop Word Color; WCST CAT: Test of Wisconsin Categories; WCSN PERSEV.ERR: Wisconsin card sorting - Perseverative errors; CONTROL 
MEN: Subscale of Wechsler of Mental Control.
It should be noted that neuropsychological variables do 
not show interdependence in the model. It is ruled out that 
there is multicollinearity, or linear autocorrelation. The first 
aspect measured by the inflation factors of variance that did 
not exceed 10, the diagnoses of collinearity less than 30 and 
the coefficient above 0.9. The second aspect obtained by the 
Dubin-Watson statistic is 2.111, which assumes that the re-
siduals are independent and complies with the fact that 
there is no serial autocorrelation. Also, when applying the 
test of normality to the waste (Kolmogorov-Smirnov test) 
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generates a Z statistic of 0.379, with a p-value=0.996. This 
indicates that the assumption of the normality of the resi-
dues is fulfilled.
The linear regression model performed in the control 
group did not show significant results (p<0.73); similarly, 
the model only accounts for 43.5% of the variability of the 
cortisol profile, which implies a low adjustment. Thus, signif-
icance values  above 0.05 are found in the different neuro-
psychological and emotional variables included in the model 
(Table 4).
CONClusIONs
The group of patients with FM present significant neu-
ropsychological alterations, mainly in the attention, memo-
ry, language and executive functions, as compared to the 
control group; being specifically of relation and influence of 
the alterations of episodic memory and cognitive flexibility 
with the profile of serum cortisol, as a measure of physio-
logical stress.
Previous studies have shown that the functions of se-
lective attention and working memory are more susceptible 
to deficit in the presence of pain22. Likewise, patients with 
FM have worse performance in Stroop word-color and sym-
bol digit test as a measure of attention / executive function 
and processing speed, respectively23, as well as in the ability 
to effectively access verbal information stored in memory24. 
These evident difficulties in diminished cognitive perfor-
mance suggest alterations in the underlying brain mecha-
nisms, especially those related to reward / punishment and 
pain systems (decreased dopaminergic activity in the ventral 
tegmental area and decreased gray matter in regions of the 
cingulate cortex, Prefrontal medial, parahippocampal gyrus, 
fusiform cortex and cerebellum areas), evidenced in func-
tional magnetic resonance imaging (MRI)25,26.
On the other hand, when measuring the physiological 
stress variable by means of the AM-PM cortisol test, and 
analyzing the difference of both measures (cortisol profile), 
it was found that there are no significant differences be-
tween patients with FM and the control group, contrary to 
what has been found in previous reviews15. However, the 
findings show that, in the FM group, there are significant 
correlations between the cortisol profile and memory stor-
age capacity and the ability to be flexible and change strat-
egy against the demands of the environment. This negative 
correlation, indicates that the greater the stress, the lower 
the performance in memory activities and cognitive flexibil-
ity, which suggests that physiological stress can be consid-
ered a factor that interferes in the neuropsychological alter-
ations of these patients, especially in work memory tasks 
and surveillance, which are related to salivary cortisol mea-
surements, as reported in previous studies27. Likewise, in the 
control group, similar correlations were found; which may 
suggest that stress in non-pathological subjects may influ-
ence cognitive performance specifically in attention, memo-
ry, or executive functions, even though these difficulties are 
not clinically significant28.
In the same vein, the results of the multiple regression 
analysis indicate that some of the neuropsychological alter-
ations found mainly in memory and executive functions, as 
well as the symptoms of depression, are related to and pre-
dict the variability in cortisol levels, this due to the existing 
and documented relationship of cognitive processes and the 
neuroendocrine system: the stress associated with glucocor-
ticoid activation that causes declining declarative memory29, 
poor self-regulation capacity and inhibition of executive 
function responses that maintains the chronic pain condi-
tion30 and the symptoms of anxiety and depression are relat-
ed to alterations in the endocrine system, which sustained 
over time affects the cognitive processes31. On the other 
hand, it has been demonstrated that there is a relationship 
between cortisol levels and cognitive functions, probably 
mediated by the activation and feedback of the hypotha-
lamic-pituitary-adrenal system, with the prefrontal cortex, 
which has high concentrations of corticosteroid receptors 
and are responsible for the regulation of affect, autonomic 
reactions to harmful stimuli, learning and memory32.
The findings of this study, besides confirming alter-
ations in specific cognitive domains in FM patients and 
demonstrating the probably two-way relationship between 
physiological stress, neuropsychological variables and de-
pression, suggest the presence of more complex mechanisms 
underlying the symptoms of disease, involving the participa-
tion of different functional brain systems. On the other 
hand, cognitive and affective systems have been shown to 
be involved in disorders related to pain perception; specifi-
cally, the ventromedial prefrontal cortex and the accumbens 
nucleus, which form a system that evaluates the relevance 
and affective value of the stimulus by controlling the flow 
of information through descending pathways33.
The identification of these neurophysiological processes 
involved in this disease allows for a multimodal diagnostic 
and therapeutic approach, in which a holistic view of the 
patient must be taken, which is in line with a more compre-
hensive bio-psycho-social model. Finally, in the present 
study, we can point out methodological difficulties related 
to the sample size and the representation of the female gen-
der in the whole sample. This is partly explained by the high-
er prevalence of the disease in women than in men. As a 
recommendation for future research, it is important to take 
into account the influence of the time of evolution and the 
history of treatments that the patient has received, in the 
development of the symptoms of the disease, in order to be 
9Actas Esp Psiquiatr 2018;46(1):1-11
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able to understand more accurately the relations of influ-
ence between each of the variables that affect the disorder.
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